Loading clinical trials...
Loading clinical trials...
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Galderma R&D
NCT04985916 · Lateral Canthal Lines, LCL, Crow's Feet
NCT04157686 · Glabellar Lines, Lateral Canthal Lines
NCT03911102 · Lateral Canthal Lines
NCT04225260 · Glabellar Lines, Lateral Canthal Lines
NCT03655691 · Lateral Canthal Lines, Crow's Feet
Ablon Skin Institute and Research Center
Manhattan Beach, California
Dermatology Cosmetic Laser Medical Associates
San Diego, California
Art of Skin, MD
Solana Beach, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions